4UPJ

HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U097410 [4-HYDROXY-3-[1-[3-[[[[(TERT-BUTYLOXYCARBONYL) AMINOMETHYL]CARBONYL]AMINO]PHENYL]PROPYL]COUMARIN

Summary for 4UPJ

• Entry DOI: 10.2210/pdb4upj/pdb
• Descriptor: HIV-2 PROTEASE, ({3-[1-(4-HYDROXY-2-OXO-2H-CHROMEN-3-YL)-PROPYL]-PHENYLCARBAMOYL}-METHYL)-CARBAMIC ACID TERT-BUTYL ESTER (3 entities in total)
• Functional Keywords: hydrolase (acid protease)
• Biological source: Human immunodeficiency virus 2
• Cellular location: Matrix protein p17: Virion (Potential). Capsid protein p24: Virion (Potential). Nucleocapsid protein p7: Virion (Potential). Reverse transcriptase/ribonuclease H: Virion (Potential). Integrase: Virion (Potential): P04584
• Total number of polymer chains: 2
• Total formula weight: 21877.13

Authors

Watenpaugh, K.D.,Mulichak, A.M.,Janakiraman, M.N. (deposition date: 1996-03-04, release date: 1996-10-14, Last modification date: 2024-04-03)

Primary citation

Thaisrivongs, S.,Watenpaugh, K.D.,Howe, W.J.,Tomich, P.K.,Dolak, L.A.,Chong, K.-T.,Tomich, C.-S.C.,Tomasselli, A.G.,Turner, S.R.,Strohbach, J.W.,Mulichak, A.M.,Janakiraman, M.N.,Moon, J.B.,Lynn, J.C.,Horng, M.-M.,Hinshaw, R.R.,Curry, K.A.,Rothrock, D.J.
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
J.Med.Chem., 38:3624-3637, 1995

PubMed Abstract: The low oral bioavailability and rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover nonpeptidic HIV protease inhibitors had previously identified compound II (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of HIV protease complexes containing the peptide-derived inhibitor I (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3 (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as phenprocoumon (compound II), provided a rational basis for the structure-based design of more active analogues. This investigation reports on the important finding of a carboxamide functionally appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone templates which resulted in a new promising series of nonpeptidic HIV protease inhibitors with improved enzyme-binding affinity. The most active diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1 protease with a K(i) value of 0.0014 muM. This research provides a new design direction for the discovery of more potent HIV protease inhibitors as potential therapeutic agents for the treatment of HIV infection.

PubMed: 7658450
DOI: 10.1021/jm00018a023

Experimental method

X-RAY DIFFRACTION (1.9 Å)